The vaccine is in its phase II study. Fifty patients with glioblastoma brain tumors are receiving the vaccine along with temozolomide chemotherapy.
Here are five points:
1. Robert Fenstermaker, MD, and Michael Ciesielski, PhD, created the vaccine.
2. SurVaxM, which mimics peptide, attacks survivin cell-survival protein.
3. Researchers saw positive results from the vaccine in preclinical studies.
4. Exhibiting low toxicity, SurVaxM was used in preclinical studies that saw the patients living for more than a year. Many patients with glioblastoma tumors don’t survive more than eight months.
5. If the studies continue to show positive results, researchers may apply the vaccine in melanoma, ovarian and prostate tumor cases, as well.
More articles on quality & infection control:
5-step handwashing helps reduce sickness-related absenteeism for students — 5 things to know
Research paves way for MRSA vaccine — 5 findings
Lean approach reduces OR instrument use by 70% for MIS surgery: 4 insights from a new study
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.